[The treatment of myocardial infarct with streptokinase].
The current situation concerning the use of Streptokinase in the treatment of recent myocardial infarction does not make it possible to draw any definite conclusions with regard to its therapeutic value:--mortality would not appear to be significantly modified in the majority of series;--the occurrence rate of major complications during the acute phase is not notably altered but it seems possible that the electrocardiographic course of the necrosis is more favourable under the influence of Streptokinase when treatment is begun early. The long term course cannot be assessed. Finally, it is certain that the tolerance of Streptokinase therapy has been good in all the published series. In particular, Streptokinase does not appear to have been associated with severe haemorrhagic complications nor a higher prevalence of cardiac rupture.
D001809:Blood Viscosity / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D006341:Heart Rupture / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007362:Intensive Care Units; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use*
D013300:Streptokinase
Le traitement de l'infarctus du myocarde par la streptokinase.